DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Iron Deficiency Anemia Market Growth Anticipated to Fuel at a CAGR of 3.7% by 2030 Visit Post
2 AstraZeneca's Ultomiris; HebaBiz's Siroquine; Pfizer's XELJANZ; Bristol Myers Squibb's Opdivo; and Masimo's PVi Visit Post
3 Fecal Incontinence Therapeutics Market Surges with Innovative Therapies in the Pipeline Visit Post
4 Unity's advanced vascular eye disease trial; Rallybio raises $100 M; Sanofi bets over $1B for Eureka's candidate; Lilly invests in MiNA; Visit Post
5 Wearable Devices: Weighing the Potential Benefits and Pitfalls of the Innovative Wearable Products Visit Post
6 InnoCare's Trial In China; Sanofi/GSK COVID-19 Vaccine; Apellis’s Empaveli for PNH; LianBio, Landos Collab Visit Post
7 Ocugen-Bharat Biotech’s Covaxin Against B.1.617 Corona Variant; uniQure Shares; J&J Covid Vaccine; Sanofi-Moderna COVID Vaccine Deal Visit Post
8 Vertex leads in CRISPR Therapeutics deal; Update for Phase 2 clinical trial of KVD824; Ovid dumps lead program; Virta Health pulls in $133M Visit Post
9 Cidara Therapeutics and J&J’s USD 780M Deal; FDA’s Approval to Supernus’s ADHD drug; Rain Therapeutics USD 100M IPO; NMPA Approval to Antengene’s ATG-019 IND Application Visit Post
10 A New Addition to Existing Chimeric Antigen Receptor Therapies –Potential for a Game Changer in Blood Cancers Visit Post
11 Amgen to acquire Rodeo for $55M; Novartis expands radioligand portfolio; Organon acquires Alydia for $240M; Forma announces positive FT-4202 dose levels Visit Post
12 Bleeding Disorders: How Key Companies Are Shaping The Bleeding Disorders Therapeutics Market? Visit Post
13 Hemophilia B Market: How Pipeline Therapies are Transforming the Treatment Hemisphere? Visit Post
14 A Royal Disease: Hemophilia Visit Post
15 Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer Visit Post
16 Hypofibrinogenemia Market: Limited Pipeline Therapies, Abundant Opportunities Visit Post
17 Merck, Eisai in renal cancer market; G1 Therapeutics on Cosela’s approval; Takeda's Maribavir; Astellas/Seagen Padcev Visit Post
18 Verily - Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis Visit Post
19 Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1401; Prothena brings AL amyloidosis drug back; Canon Medical expands its MRI AI programs Visit Post
20 Thrombocytopenia Drugs Market: What Newer Agents Are Expected To Enter The Market? Visit Post
21 Increasing Prevalence and Upcoming Novel Therapeutic Approaches: What is Shaping the Hepatitis D Market Outlook? Visit Post
22 Evolution in Hepatitis B and C Virus: Can we expect success similar to Hepatitis C in Hepatitis B as well? Visit Post
23 Overcoming the prevailing unmet needs in Beta-Thalassemia Market Visit Post
24 Vir's drug shows results; Abbott launches coronavirus antibody lab test; Reprogrammed skin cells repair vision in mouse models; Moma Therapeutics focuses for molecular machines Visit Post
25 Warm Autoimmune Hemolytic Anemia: A less prevalent disease with prevailing unmet needs Visit Post
26 Warm Autoimmune Hemolytic Anemia Epidemiology forecast segmentation, treatment approaches, and WAIHA market forecast Visit Post
27 Gilead to buy Forty Seven; Akrevia Therapeutics unveils new identity; FDA approved pyrimethamine Visit Post
28 GBT, Syros; Takeda, Cevance collaborates; IND application to ZN-c3 Visit Post
29 Wave Life Sciences stocks implode; Amarin’s VASCEPA approval; GSK seeks approval Visit Post
30 Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval Visit Post
31 Novel treatment approval promises a better future for Sickle cell disease patients Visit Post
32 How Gene therapy is changing the Beta-thalassemia Treatment outlook? Visit Post
33 The long journey of Biosimilars: Is it an emerging opportunity? Visit Post
34 GHO to advance healthcare in Europe; Truvian nets USD 27.1 Mn; Lilly plans its diabetes portfolio expansion Visit Post
35 Beta-Thalassemia Pharmacological Therapies Visit Post
36 FDA declines the approval of Lipocine’s testosterone drug; Novartis Sandoz to buy Aspen Pharmacare Japanese Unit Visit Post
37 Themis Bioscience collaborates with Merck; Oncorus raises USD 80 M; GSK files for Japanese approval of anaemia drug Visit Post
38 Myelofibrosis Therapeutics Market Visit Post
39 World Sickle Cell Day Visit Post
40 World Blood Donor Day Visit Post
41 World Thalassemia Day Visit Post
42 World Haemophilia Day Visit Post
43 Multiple Myeloma Day Visit Post
44 The changing landscape of Multiple Myeloma therapies market Visit Post
45 The Business Cocktail Visit Post
46 BridgeBio bags $299M; Immunochina receives $20M; Attune raises; Wren receives $23M Visit Post
47 Notizia Visit Post
48 Gilead remunerates; Roche taps Halozyme’s drug delivery tech; Orchard Therapeutics prices its IPO Visit Post
50 Copiktra receives approval; Lilly wins approval; Eisai’s Fycompa; Astellas’ Roxadustat; Janssen’s Esketamine Nasal Spray Visit Post
51 Companion Diagnostics Visit Post
52 Snippet Visit Post
53 Biologic Parallel – A Perky Future Ahead Visit Post
54 Notizia Visit Post
55 Key Clinical Outcomes- 30/07/2018 Visit Post
56 Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set to refile ozanimod Visit Post
57 Hemophilia A- Market Scenario Visit Post
58 Novartis’s Entresto; AZ, J&J and Lilly sharply cut death rates; CAR-T drugs worth; FDA warns Visit Post
59 Business Cocktail Visit Post
60 Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2020 Visit Post
61 Hemophilia - Market Insights, Epidemiology and Market Forecast-2020 Visit Post
62 A Glimpse of the Anticoagulants Therapy Market; Major Players Visit Post
63 Anticoagulants Market A Big Boom Visit Post
64 DelveInsight’s Hematological disorders based Gene Therapy Reports Visit Post
65 Global Hemophilia Market Visit Post